21-Year Study Shows Lifestyle Changes Slash Multimorbidity Risk in Prediabetes
A landmark 21-year trial finds diet and exercise interventions cut multimorbidity risk by 21% in prediabetic adults — metformin showed no such benefit.
Summary
A 21-year follow-up of the Diabetes Prevention Program trial reveals that lifestyle interventions — focused on diet and exercise — reduced the risk of developing multiple chronic conditions by 21% in adults with prediabetes. Metformin, by contrast, showed no significant benefit for multimorbidity. Over 80% of all participants eventually developed at least two chronic conditions, including hypertension, heart disease, diabetes, and dementia. Participants who progressed to full diabetes faced a 33% higher multimorbidity risk regardless of treatment. Researchers suggest lifestyle changes work by improving inflammation, metabolic regulation, and cellular aging. The findings reinforce that sustainable diet and exercise habits offer broad, lasting protection well beyond diabetes prevention alone.
Detailed Summary
For adults with prediabetes, the stakes of lifestyle choices extend far beyond blood sugar control. A landmark 21-year follow-up study published in JAMA reveals that structured diet and exercise interventions significantly reduce the risk of developing multimorbidity — the presence of two or more chronic diseases simultaneously — one of the most burdensome and costly health outcomes in aging populations.
The study drew on long-term data from the Diabetes Prevention Program (DPP) trial, one of the most rigorous prevention trials ever conducted. Adults with prediabetes were randomized to lifestyle intervention, metformin, or placebo. After 21 years, those in the lifestyle group had a 21% lower risk of multimorbidity compared to placebo (HR 0.79). Metformin showed no statistically significant benefit on this outcome. Chronic conditions tracked included hypertension, heart failure, stroke, dementia, cancer, depression, and osteoporosis, among others.
Despite the protective effect of lifestyle change, the overall burden remained high: 82% of the lifestyle group still developed at least two chronic conditions, versus 87% in the placebo group. This highlights both the power and the limits of behavioral intervention — meaningful risk reduction, but not elimination. Participants who progressed to type 2 diabetes carried a 33% higher multimorbidity risk independent of their treatment group, underscoring diabetes itself as a major driver of downstream disease.
Researchers propose the mechanisms involve improvements in systemic inflammation, metabolic regulation, and cellular aging processes — all hallmarks of longevity science. These pathways suggest lifestyle intervention works on a biological level that extends well beyond glucose management.
For health-optimizing adults, the practical message is clear: diet and exercise habits adopted during prediabetes can deliver compounding protective effects across multiple disease domains over decades. The editorialists also flagged GLP-1 receptor agonists like semaglutide and tirzepatide as emerging candidates for multimorbidity prevention, though long-term evidence remains limited.
Key Findings
- Lifestyle intervention reduced multimorbidity risk by 21% over 21 years compared to placebo in prediabetic adults.
- Metformin showed no significant reduction in multimorbidity risk despite its known diabetes-prevention benefits.
- Over 82–87% of all participants developed at least two chronic conditions regardless of treatment group.
- Progression to type 2 diabetes independently raised multimorbidity risk by 33%, highlighting diabetes control as critical.
- Lifestyle changes likely work via reduced inflammation, improved metabolic regulation, and slower cellular aging.
Methodology
This is a news report summarizing a peer-reviewed study published in JAMA, based on 21-year follow-up data from the Diabetes Prevention Program (DPP) — a well-powered, randomized controlled trial. The source, MedPage Today, is a credible medical journalism outlet; findings are attributed to named researchers from the National Institute on Aging.
Study Limitations
The article does not detail specific lifestyle intervention components (intensity, diet type, exercise duration), limiting direct replication. Multimorbidity outcomes relied on a predefined condition list that may not capture all relevant diseases. Long-term adherence to lifestyle interventions was not fully described; real-world compliance may differ from trial conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.